{"id":924,"date":"2025-02-10T14:02:09","date_gmt":"2025-02-10T14:02:09","guid":{"rendered":"https:\/\/www.bayraklaw.com\/?post_type=portfolio&#038;p=924"},"modified":"2025-02-11T11:19:00","modified_gmt":"2025-02-11T11:19:00","slug":"sosyal-guvenlik-kurumunun-sgk-karsilamadigi-kanser-ilaclari-icin-hukuki-yollar","status":"publish","type":"portfolio","link":"https:\/\/www.bayraklaw.com\/en\/bultenler\/sosyal-guvenlik-kurumunun-sgk-karsilamadigi-kanser-ilaclari-icin-hukuki-yollar\/","title":{"rendered":"Legal Ways for Cancer Medications Not Covered by the Social Security Institution"},"content":{"rendered":"<p style=\"font-weight: 400;\"><span style=\"font-size: 17px;\">During the cancer treatment process, patients and their families face various challenges. Among these challenges, cancer medications not covered by the Social Security Institution (SSI) are at the forefront.<\/span><\/p>\n<p style=\"font-weight: 400;\"><span style=\"font-size: 17px;\">The financing of necessary medications for cancer patients is shaped according to the criteria set by SSI. SSI's regulations regarding healthcare services are addressed under the Health Implementation Communiqu\u00e9, which clearly defines which medications are covered by reimbursement.<\/span><\/p>\n<p style=\"font-weight: 400;\"><span style=\"font-size: 17px;\">According to Article 4.1.9 \u2013 Medications to be Paid for (APPENDIX-4\/A) of the Health Implementation Communiqu\u00e9, medications to be covered by SSI are listed in the \"List of Medications to be Paid for (APPENDIX-4\/A)\" published on the Institution's official website. As clearly stated in the Communiqu\u00e9, medications that do not have a commercial name and barcode\/QR code number in this list will not be reimbursed by SSI under any circumstances. However, it is noted that special regulations regarding medications obtained from abroad are excluded from this scope.<\/span><\/p>\n<p style=\"font-weight: 400;\"><span style=\"font-size: 17px;\">This regulation emphasizes SSI's authority to determine which medications are covered under reimbursement, while also causing significant issues for patients.<\/span><\/p>\n<p style=\"font-weight: 400;\"><span style=\"font-size: 17px;\">In particular, the immunotherapy and chemotherapy medications not covered by SSI create a significant financial burden for patients. This situation leads some patients to seek legal avenues to demand that the state covers the cost of the medications. In this article, we will provide detailed information on the legal processes and steps involved in filing a lawsuit to access cancer medications that are not covered by the state.<\/span><\/p>\n<h2 style=\"font-weight: 400;\"><span style=\"font-size: 17px;\"><strong>1.  Doctor's Application<\/strong><\/span><\/h2>\n<p style=\"font-weight: 400;\"><span style=\"font-size: 17px;\">Firstly, your doctor needs to submit an application to the Turkish Medicines and Medical Devices Agency under the Ministry of Health. The application should include convincing statements such as the unavailability of an equivalent medication, the life-threatening nature of the condition, and the necessity of the medication for maintaining the patient's quality of life.<\/span><\/p>\n<h2 style=\"font-weight: 400;\"><span style=\"font-size: 17px;\"><strong>2.   Written Petition to the Social Security Institution (SSI)<\/strong><\/span><\/h2>\n<p style=\"font-weight: 400;\"><span style=\"font-size: 17px;\">For immunotherapy and smart drugs, which are proposed for the treatment of cancer and are not covered by SSI, the patient, the patient's family members, or their representative must first submit a petition to the Health Social Security Center of the SSI Provincial Directorate to request that the medication be covered by SSI and to seek reimbursement for the paid medication costs.<\/span><\/p>\n<p style=\"font-weight: 400;\"><span style=\"font-size: 17px;\">At this stage, it is important to express your request in a way that covers the entire treatment process without interruption when applying to SSI. Otherwise, if you wish to expand your request later, you may need to apply again.<\/span><\/p>\n<p style=\"font-weight: 400;\"><span style=\"font-size: 17px;\">The application to SSI is a prerequisite for both the Labor Court and the Administrative Court. It is not possible to file a lawsuit regarding cancer medications without completing this procedure. Therefore, to initiate the legal process, an application to the administration must be made first.<\/span><\/p>\n<p style=\"font-weight: 400;\"><span style=\"font-size: 17px;\">The written application must include the name of your cancer, information about the hospitals where you have been examined and tested, and the name of the cancer medication you wish to be covered. The petition must be accompanied by documents such as the diagnosis report for the illness, the official certified version of the medication usage report, and the original certified version of the prescription issued by the doctor, including the doctor's stamp and protocol number.<\/span><\/p>\n<p style=\"font-weight: 400;\"><span style=\"font-size: 17px;\"><strong>Documents That Must Be Included in the Initial Application to SSI:<\/strong><\/span><\/p>\n<ol>\n<li><span style=\"font-size: 17px;\"><strong>The original certified version of the prescription<\/strong><\/span><\/li>\n<li><span style=\"font-size: 17px;\"><strong>The original certified version of the medication usage report<\/strong><\/span><\/li>\n<li><span style=\"font-size: 17px;\"><strong>The approval for Off-Label Drug Use issued by the Ministry of Health's Medical Devices and Pharmaceuticals Agency, submitted by your doctor<\/strong><\/span>\n<ul>\n<li><span style=\"font-size: 17px;\">Before applying to SSI for cancer medications not covered by SSI, your doctor must first obtain approval from the Turkish Medicines and Medical Devices Agency for off-label drug use. While this approval can sometimes be granted easily, it may be rejected in exceptional cases. In such a situation, before filing a lawsuit for cancer medications not covered by SSI, an annulment lawsuit must be filed at the administrative court against the rejection of the off-label drug use approval.<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ol>\n<p style=\"font-weight: 400;\"><span style=\"font-size: 17px;\">Your application will be rejected based on the Health Implementation Communiqu\u00e9 of the Social Security Institution,<strong>4<\/strong>.<strong>1.9 Bedeli \u00d6denecek \u0130la\u00e7lar\u201d<\/strong><strong>\u00a0<\/strong>ba\u015fl\u0131kl\u0131 maddenin 1.bendinde yer alan \u201c<strong>\u201cArticle 4.1.9 \u2013 Medications to be Paid for, which states in section 1: \"Medications to be paid for by the Institution are listed in the 'List of Medications to be Paid for' (APPENDIX-4\/A) published on the official website of the Institution. Medications not listed with their commercial names and barcode\/QR codes will not be reimbursed under any circumstances.\"<\/strong>\u00a0d\u00fczenlemesine dayan\u0131larak reddedilecektir.<\/span><\/p>\n<h2 style=\"font-weight: 400;\"><span style=\"font-size: 17px;\"><strong>3. Filing a Lawsuit Against the Social Security Institution (SSI)<\/strong><\/span><\/h2>\n<p style=\"font-weight: 400;\"><span style=\"font-size: 17px;\">You can file a lawsuit against SSI after your application is rejected or if the legal response period of 60 days has passed (Article 4, Labor Courts Law No. 7036). A lawsuit for reimbursement of medication costs from SSI can only be filed after a rejection decision or if no response is provided within 60 days, starting from the 60th day after the application. Otherwise, the lawsuit will be dismissed due to the absence of the required procedural condition.<\/span><\/p>\n<p style=\"font-weight: 400;\"><span style=\"font-size: 17px;\">According to Article 101 of the Social Insurance Law No. 5510, in cases where there is no contrary provision, disputes arising from this law fall under the jurisdiction of the labor courts. A similar provision is also found in Article 5 of the Labor Courts Law No. 7036. Therefore, the competent court for lawsuits seeking reimbursement of cancer medications is, in principle, <strong>the Labor Court.<\/strong>The competent court is the one located in the area of the SSI Provincial Directorate to which the patient is registered.<\/span><\/p>\n<p><span style=\"font-size: 17px;\">It is worth mentioning an exception regarding the competent court for civil servants and public employees. According to the decisions of the Court of Cassation (10th Civil Chamber, E. 2017\/2735, K. 2019\/5127, 18.06.2019) and the Dispute Court (Dispute Court, E. 2020\/530, K. 2020\/634, 26.10.2020), those who worked as civil servants or public employees before the enactment of the Social Insurance and General Health Insurance Law No. 5510 will continue to be subject to the provisions of the Law No. 5434, and the actions taken by SSI will remain classified as \"administrative actions.\" Lawsuits filed to annul such actions should be resolved in the administrative courts. <strong data-start=\"139\" data-end=\"196\">5434 Say\u0131l\u0131 T\u00fcrkiye Cumhuriyeti Emekli Sand\u0131\u011f\u0131 Kanunu <\/strong>h\u00fck\u00fcmlerine tabi olmaya devam edece\u011finden Sosyal G\u00fcvenlik Kurumunca tesis edilen i\u015flem ve yapaca\u011f\u0131 muamelelerin \u201cidari i\u015flem\u201d ve \u201cidari eylem\u201d niteli\u011fini korumaya devam edecektir. S\u00f6z konusu i\u015flem veya eylemin iptali i\u00e7in a\u00e7\u0131lan davalar\u0131n \u00e7\u00f6z\u00fcm yerinin idari yarg\u0131 yeri oldu\u011fu istikrarla ifade edilmi\u015ftir.<\/span><\/p>\n<p><span style=\"font-size: 17px;\">In summary, civil servants and public employees who worked before the enforcement date of Law No. 5510 (June 16, 2006) will remain subject to the provisions of Law No. 5434, and administrative courts will have jurisdiction. However, civil servants and public employees who started their duties after the enactment of Law No. 5510 will be considered insured under Article 4\/c of Law No. 5510 and will be subject to the provisions of this law. Therefore, disputes related to these individuals will be resolved in judicial courts.<\/span><\/p>\n<ul>\n<li><span style=\"font-size: 17px;\"><strong>Filing a Request for a Provisional Injunction Against the Social Security Institution (SSI)<\/strong><\/span><\/li>\n<\/ul>\n<p style=\"font-weight: 400;\"><span style=\"font-size: 17px;\">When a claim is made for the reimbursement of cancer treatment drugs, such as immunotherapy and smart drugs, that should be covered by SSI during the course of treatment, and when the institution's decision to reject the request is contested, the petition to the competent court should be\u00a0<strong>accompanied by a request for a provisional injunction.<\/strong>\u00a0olmal\u0131d\u0131r.<\/span><\/p>\n<p style=\"font-weight: 400;\"><span style=\"font-size: 17px;\">Provisional injunctions are governed under Articles 389 and following of the Civil Procedure Code No. 6100 (HMK). Article 389, titled \"Conditions for Provisional Injunction,\" states:<strong>\u00a0<\/strong><strong>\u201c\u0130htiyati Tedbirin \u015eartlar\u0131\u201d<\/strong><strong>\u00a0<\/strong>ba\u015fl\u0131kl\u0131 389. maddesi; \u201c<strong>\"A provisional injunction may be granted when there is concern that a change in the current situation may significantly hinder or completely make it impossible to obtain the right, or that a delay could result in harm or danger.\" <\/strong><strong>karar\u0131<\/strong><strong> verilebilir<\/strong>The law sets out the conditions for granting a provisional injunction. It recognizes situations where a change may make obtaining the right substantially more difficult or impossible, where there is a concern that delay will result in a harm or serious damage, or where urgency is required.\u00a0<strong>In claims involving the reimbursement of imported cancer drugs, in addition to the urgency, it is necessary to demonstrate a probable cause of the claim, as per Article 390\/3 of the HMK. <\/strong><strong>imk\u00e2ns\u0131z<\/strong><strong> hale gelece\u011fi veya gecikmesinde sak\u0131nca bulunmas\u0131 yahut ciddi bir zarar\u0131n ortaya \u00e7\u0131kaca\u011f\u0131 endi\u015fesi bulunan haller<\/strong>This means the plaintiff must show, through a prima facie case, that the refusal to grant the provisional injunction could pose a life-threatening situation for the patient.\n\nTo demonstrate the merits of the claim (probable cause), the following evidence should be provided in the case file:<\/span><\/p>\n<h2 style=\"font-weight: 400;\"><span style=\"font-size: 17px;\"><strong>Evidence Required for a Successful Claim<\/strong><\/span><\/h2>\n<p style=\"font-weight: 400;\"><span style=\"font-size: 17px;\">Submitting a complete set of documents when applying to SGK is crucial for the smooth and timely progression of the process. Below are the required documents for the application and details regarding each:<\/span><\/p>\n<ol>\n<li><span style=\"font-size: 17px;\"><strong>Rejection Letter by the SSI <\/strong>The application letter made for the reimbursement of the mentioned drug by SSI or the refund of the amount paid for the drug, along with the rejection decision given by the institution, must be included in the lawsuit file.<\/span><\/li>\n<li><span style=\"font-size: 17px;\"><strong>Pathology Report:<\/strong> The pathology report, which includes all diagnostic, diagnostic, treatment, and examination documents, images, films, and similar records related to the patient, must be included in the lawsuit file. All radiological examinations (including PET\/CT scans) and radiology reports, as well as imaging tests like tomography and MR, must also be included. If available, the report of imaging tests showing the response after the patient has been treated with the drug should also be included (it is generally requested to be sent in DICOM format, i.e., on a CD).<\/span><\/li>\n<li><span style=\"font-size: 17px;\"><strong>Discharge Summary Report:<\/strong>The discharge summary is a report type that begins to be prepared when the patient presents to the healthcare facility. This report includes the drugs used for the patient, the tests performed, the diagnosis made, the results of the treatment, and, if surgery was performed, all examinations conducted in the order of the operation. The discharge summary report must contain: i) all the doctor\u2019s discharge summary reports related to the disease in question, and ii) the doctor's discharge reports showing the chemotherapy\/radiotherapy treatments applied. <strong>i)<\/strong> s\u00f6z konusu hastal\u0131k nedeniyle d\u00fczenlenen t\u00fcm doktor epikriz raporlar\u0131n\u0131 ve <strong>ii)<\/strong> uygulanan kemoterapi\/radyoterapi tedavilerini g\u00f6sterir doktora epikriz raporlar\u0131n\u0131 i\u00e7ermesi gerekir.<\/span><\/li>\n<li><span style=\"font-size: 17px;\"><strong>Tumor Tissue Reports:<\/strong> All studies related to the tumor tissues taken from the patient (biopsy reports, genetic analysis reports, etc.) must be included.<\/span><\/li>\n<li><span style=\"font-size: 17px;\"><strong>Doctor\u2019s Report Certifying the Condition:<\/strong> A health board report is required, explaining the patient's health condition and the necessity of using chemotherapy or immunotherapy drugs not covered by SSI. This report should explain the benefits of the drugs on the patient's health and how their health condition will be negatively affected if these drugs are not used.<\/span><\/li>\n<li><span style=\"font-size: 17px;\"><strong>Off-Label Approval Report:<\/strong><strong>: <\/strong>Any use of a drug outside its approved indication and the dosage described in the brief product information requires off-label drug use approval from the<strong>\"Turkish Medicines and Medical Devices Agency,\"<\/strong>which is affiliated with the Ministry of Health. The patient's doctor submits an application to the institution, which evaluates and makes a decision. If the Turkish Medicines and Medical Devices Agency does not approve the off-label use of the drug, the decision made by the institution is considered an administrative act.\u00a0<strong>Therefore, a Cancellation Case with a Request for a Stay of Execution must be filed with the Administrative Court within 30 DAYS to annul the administrative decision made by the institution.<\/strong>\u00a0tesis etti\u011fi idari i\u015flemin iptali i\u00e7in\u00a0<strong>3<\/strong><strong>0 G\u00dcN<\/strong>\u00a0i\u00e7inde y\u00fcr\u00fctmeyi durdurma talepli\u00a0<strong>\u0130PTAL DAVASI<\/strong> a\u00e7\u0131lmas\u0131 gerekmektedir.<\/span><\/li>\n<li><span style=\"font-size: 17px;\"><strong>\u0130<\/strong><strong>Prescription:<\/strong>All prescriptions issued by doctors for immunotherapy or smart drugs to be used in cancer treatment must be included in the lawsuit file.<\/span><\/li>\n<li><span style=\"font-size: 17px;\"><strong>Drug Use Report:<\/strong>A drug use report issued by the doctor regarding immunotherapy or smart drugs to be used in cancer treatment must be included in the lawsuit file.<\/span><\/li>\n<li><span style=\"font-size: 17px;\"><strong>Invoice:<\/strong>If payment has been made for immunotherapy or smart drugs required for cancer treatment, the payment slip and invoice for this payment must be included in the lawsuit file.<\/span><\/li>\n<li><span style=\"font-size: 17px;\"><strong>Doctor\u2019s Report on the Use of the Drug and Disease Progression:<\/strong> A report from the patient\u2019s own doctor should be submitted during the lawsuit process regarding the use of the drug and its effect on the disease progression, within the scope of the provisional injunction granted by the court.<\/span><\/li>\n<\/ol>\n<p style=\"font-weight: 400;\"><span style=\"font-size: 17px;\"><strong>Some drugs used in immunotherapy and smart drug treatment are not covered by SSI. Below is a list showing whether some commonly used drugs in treatment are covered by SSI:<\/strong><\/span><\/p>\n<table style=\"font-weight: 400; height: 790px;\" width=\"938\">\n<tbody>\n<tr>\n<td width=\"195\"><span style=\"font-size: 17px;\"><strong>Drug Name<\/strong><\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\"><strong>Active Ingredient<\/strong><\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\"><strong>Status<\/strong><\/span><\/td>\n<\/tr>\n<tr>\n<td width=\"195\"><span style=\"font-size: 17px;\">Keytruda<\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\">Pembrolizumab<\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\">Not Reimbursed<\/span><\/td>\n<\/tr>\n<tr>\n<td width=\"195\"><span style=\"font-size: 17px;\">Opdivo<\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\">Nivolumab<\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\">Covered Since 2018<\/span><\/td>\n<\/tr>\n<tr>\n<td width=\"195\"><span style=\"font-size: 17px;\">Altuzan<\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\">Bevacizumab<\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\">Covered<\/span><\/td>\n<\/tr>\n<tr>\n<td width=\"195\"><span style=\"font-size: 17px;\">Cyramza<\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\">Ramucirumab<\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\">Not Reimbursed<\/span><\/td>\n<\/tr>\n<tr>\n<td width=\"195\"><span style=\"font-size: 17px;\">Imfinzi<\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\">Durvalumab<\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\">Not Reimbursed<\/span><\/td>\n<\/tr>\n<tr>\n<td width=\"195\"><span style=\"font-size: 17px;\">Lynparza<\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\">Olaparib<\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\">Covered Since 2021<\/span><\/td>\n<\/tr>\n<tr>\n<td width=\"195\"><span style=\"font-size: 17px;\">Perjeta<\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\">Pertuzumab<\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\">Covered Since 2016<\/span><\/td>\n<\/tr>\n<tr>\n<td width=\"195\"><span style=\"font-size: 17px;\">Reampla<\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\">Palbosiklib<\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\">Covered Since 2020<\/span><\/td>\n<\/tr>\n<tr>\n<td width=\"195\"><span style=\"font-size: 17px;\">Tagrisso<\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\">Osimertinib<\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\">Covered Since 2018<\/span><\/td>\n<\/tr>\n<tr>\n<td width=\"195\"><span style=\"font-size: 17px;\">Valamor<\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\">Ribosiklib<\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\">Covered Since 2020<\/span><\/td>\n<\/tr>\n<tr>\n<td width=\"195\"><span style=\"font-size: 17px;\">Bavencio<\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\">Avelumab<\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\">Covered Since 2024<\/span><\/td>\n<\/tr>\n<tr>\n<td width=\"195\"><span style=\"font-size: 17px;\">Besponsa<\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\">\u0130notuzumab<\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\">Covered Since 2021<\/span><\/td>\n<\/tr>\n<tr>\n<td width=\"195\"><span style=\"font-size: 17px;\">Rozlytrek<\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\">Entrectinib<\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\">Not Reimbursed<\/span><\/td>\n<\/tr>\n<tr>\n<td width=\"195\"><span style=\"font-size: 17px;\">Verzenios<\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\">Abemasiklib<\/span><\/td>\n<td width=\"195\"><span style=\"font-size: 17px;\">Not Reimbursed<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"font-weight: 400;\"><span style=\"font-size: 17px;\"><strong>\u00a0<\/strong><\/span><\/p>\n<p><span style=\"font-size: 17px;\">If you encounter legal issues during your cancer treatment process or need assistance regarding the reimbursement coverage by SSI, Bayrak Law Office is here to support you. <strong data-start=\"166\" data-end=\"284\" data-is-last-node=\"\">Contact us immediately, and let's evaluate legal solutions together to manage the process in the best possible way.<\/strong><\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-size: 17px;\"><strong>Att. Polen Bayrak<\/strong><\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>Kanser tedavisi s\u00fcrecinde hastalar ve yak\u0131nlar\u0131 \u00e7e\u015fitli zorluklarla kar\u015f\u0131la\u015fmaktad\u0131r. Bu zorluklar\u0131n ba\u015f\u0131nda ise Sosyal G\u00fcvenlik Kurumu (SGK) taraf\u0131ndan kar\u015f\u0131lanmayan kanser ila\u00e7lar\u0131 gelmektedir. Kanser hastalar\u0131 i\u00e7in gerekli olan ila\u00e7lar\u0131n finansman\u0131, SGK taraf\u0131ndan belirlenen kriterlere g\u00f6re \u015fekillenmektedir. SGK\u2019n\u0131n sa\u011fl\u0131k hizmetlerine ili\u015fkin d\u00fczenlemeleri Sa\u011fl\u0131k Uygulama Tebli\u011fi kapsam\u0131nda ele al\u0131nmakta olup, hangi ila\u00e7lar\u0131n geri &#8230; <a class=\"cz_readmore cz_readmore_no_icon\" href=\"https:\/\/www.bayraklaw.com\/en\/bultenler\/sosyal-guvenlik-kurumunun-sgk-karsilamadigi-kanser-ilaclari-icin-hukuki-yollar\/\"><span>Read More<\/span><\/a><\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","format":"standard","meta":[],"portfolio_cat":[],"portfolio_tags":[],"class_list":["post-924","portfolio","type-portfolio","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Sosyal G\u00fcvenlik Kurumu&#039;nun (SGK) Kar\u015f\u0131lamad\u0131\u011f\u0131 Kanser \u0130la\u00e7lar\u0131 i\u00e7in Hukuki Yollar - Bayrak Hukuk B\u00fcrosu<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.bayraklaw.com\/en\/bultenler\/sosyal-guvenlik-kurumunun-sgk-karsilamadigi-kanser-ilaclari-icin-hukuki-yollar\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sosyal G\u00fcvenlik Kurumu&#039;nun (SGK) Kar\u015f\u0131lamad\u0131\u011f\u0131 Kanser \u0130la\u00e7lar\u0131 i\u00e7in Hukuki Yollar - Bayrak Hukuk B\u00fcrosu\" \/>\n<meta property=\"og:description\" content=\"Kanser tedavisi s\u00fcrecinde hastalar ve yak\u0131nlar\u0131 \u00e7e\u015fitli zorluklarla kar\u015f\u0131la\u015fmaktad\u0131r. Bu zorluklar\u0131n ba\u015f\u0131nda ise Sosyal G\u00fcvenlik Kurumu (SGK) taraf\u0131ndan kar\u015f\u0131lanmayan kanser ila\u00e7lar\u0131 gelmektedir. Kanser hastalar\u0131 i\u00e7in gerekli olan ila\u00e7lar\u0131n finansman\u0131, SGK taraf\u0131ndan belirlenen kriterlere g\u00f6re \u015fekillenmektedir. SGK\u2019n\u0131n sa\u011fl\u0131k hizmetlerine ili\u015fkin d\u00fczenlemeleri Sa\u011fl\u0131k Uygulama Tebli\u011fi kapsam\u0131nda ele al\u0131nmakta olup, hangi ila\u00e7lar\u0131n geri ... Devam\u0131n\u0131 Oku\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.bayraklaw.com\/en\/bultenler\/sosyal-guvenlik-kurumunun-sgk-karsilamadigi-kanser-ilaclari-icin-hukuki-yollar\/\" \/>\n<meta property=\"og:site_name\" content=\"Bayrak Hukuk B\u00fcrosu\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-11T11:19:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.bayraklaw.com\/bultenler\/sosyal-guvenlik-kurumunun-sgk-karsilamadigi-kanser-ilaclari-icin-hukuki-yollar\/\",\"url\":\"https:\/\/www.bayraklaw.com\/bultenler\/sosyal-guvenlik-kurumunun-sgk-karsilamadigi-kanser-ilaclari-icin-hukuki-yollar\/\",\"name\":\"Sosyal G\u00fcvenlik Kurumu'nun (SGK) Kar\u015f\u0131lamad\u0131\u011f\u0131 Kanser \u0130la\u00e7lar\u0131 i\u00e7in Hukuki Yollar - Bayrak Hukuk B\u00fcrosu\",\"isPartOf\":{\"@id\":\"https:\/\/www.bayraklaw.com\/#website\"},\"datePublished\":\"2025-02-10T14:02:09+00:00\",\"dateModified\":\"2025-02-11T11:19:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.bayraklaw.com\/bultenler\/sosyal-guvenlik-kurumunun-sgk-karsilamadigi-kanser-ilaclari-icin-hukuki-yollar\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.bayraklaw.com\/bultenler\/sosyal-guvenlik-kurumunun-sgk-karsilamadigi-kanser-ilaclari-icin-hukuki-yollar\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.bayraklaw.com\/bultenler\/sosyal-guvenlik-kurumunun-sgk-karsilamadigi-kanser-ilaclari-icin-hukuki-yollar\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Anasayfa\",\"item\":\"https:\/\/www.bayraklaw.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"B\u00dcLTENLER\",\"item\":\"https:\/\/www.bayraklaw.com\/bultenler\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Sosyal G\u00fcvenlik Kurumu&#8217;nun (SGK) Kar\u015f\u0131lamad\u0131\u011f\u0131 Kanser \u0130la\u00e7lar\u0131 i\u00e7in Hukuki Yollar\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.bayraklaw.com\/#website\",\"url\":\"https:\/\/www.bayraklaw.com\/\",\"name\":\"Bayrak Hukuk B\u00fcrosu\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.bayraklaw.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.bayraklaw.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.bayraklaw.com\/#organization\",\"name\":\"Bayrak Hukuk B\u00fcrosu\",\"url\":\"https:\/\/www.bayraklaw.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.bayraklaw.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.bayraklaw.com\/wp-content\/uploads\/2025\/03\/Black-and-Yellow-Lines-Attorney-Law-Logo-2-kopyasi.png\",\"contentUrl\":\"https:\/\/www.bayraklaw.com\/wp-content\/uploads\/2025\/03\/Black-and-Yellow-Lines-Attorney-Law-Logo-2-kopyasi.png\",\"width\":1558,\"height\":860,\"caption\":\"Bayrak Hukuk B\u00fcrosu\"},\"image\":{\"@id\":\"https:\/\/www.bayraklaw.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"http:\/\/linkedin.com\/company\/bayrak-law\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sosyal G\u00fcvenlik Kurumu'nun (SGK) Kar\u015f\u0131lamad\u0131\u011f\u0131 Kanser \u0130la\u00e7lar\u0131 i\u00e7in Hukuki Yollar - Bayrak Hukuk B\u00fcrosu","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.bayraklaw.com\/en\/bultenler\/sosyal-guvenlik-kurumunun-sgk-karsilamadigi-kanser-ilaclari-icin-hukuki-yollar\/","og_locale":"en_GB","og_type":"article","og_title":"Sosyal G\u00fcvenlik Kurumu'nun (SGK) Kar\u015f\u0131lamad\u0131\u011f\u0131 Kanser \u0130la\u00e7lar\u0131 i\u00e7in Hukuki Yollar - Bayrak Hukuk B\u00fcrosu","og_description":"Kanser tedavisi s\u00fcrecinde hastalar ve yak\u0131nlar\u0131 \u00e7e\u015fitli zorluklarla kar\u015f\u0131la\u015fmaktad\u0131r. Bu zorluklar\u0131n ba\u015f\u0131nda ise Sosyal G\u00fcvenlik Kurumu (SGK) taraf\u0131ndan kar\u015f\u0131lanmayan kanser ila\u00e7lar\u0131 gelmektedir. Kanser hastalar\u0131 i\u00e7in gerekli olan ila\u00e7lar\u0131n finansman\u0131, SGK taraf\u0131ndan belirlenen kriterlere g\u00f6re \u015fekillenmektedir. SGK\u2019n\u0131n sa\u011fl\u0131k hizmetlerine ili\u015fkin d\u00fczenlemeleri Sa\u011fl\u0131k Uygulama Tebli\u011fi kapsam\u0131nda ele al\u0131nmakta olup, hangi ila\u00e7lar\u0131n geri ... Devam\u0131n\u0131 Oku","og_url":"https:\/\/www.bayraklaw.com\/en\/bultenler\/sosyal-guvenlik-kurumunun-sgk-karsilamadigi-kanser-ilaclari-icin-hukuki-yollar\/","og_site_name":"Bayrak Hukuk B\u00fcrosu","article_modified_time":"2025-02-11T11:19:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.bayraklaw.com\/bultenler\/sosyal-guvenlik-kurumunun-sgk-karsilamadigi-kanser-ilaclari-icin-hukuki-yollar\/","url":"https:\/\/www.bayraklaw.com\/bultenler\/sosyal-guvenlik-kurumunun-sgk-karsilamadigi-kanser-ilaclari-icin-hukuki-yollar\/","name":"Sosyal G\u00fcvenlik Kurumu'nun (SGK) Kar\u015f\u0131lamad\u0131\u011f\u0131 Kanser \u0130la\u00e7lar\u0131 i\u00e7in Hukuki Yollar - Bayrak Hukuk B\u00fcrosu","isPartOf":{"@id":"https:\/\/www.bayraklaw.com\/#website"},"datePublished":"2025-02-10T14:02:09+00:00","dateModified":"2025-02-11T11:19:00+00:00","breadcrumb":{"@id":"https:\/\/www.bayraklaw.com\/bultenler\/sosyal-guvenlik-kurumunun-sgk-karsilamadigi-kanser-ilaclari-icin-hukuki-yollar\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.bayraklaw.com\/bultenler\/sosyal-guvenlik-kurumunun-sgk-karsilamadigi-kanser-ilaclari-icin-hukuki-yollar\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.bayraklaw.com\/bultenler\/sosyal-guvenlik-kurumunun-sgk-karsilamadigi-kanser-ilaclari-icin-hukuki-yollar\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Anasayfa","item":"https:\/\/www.bayraklaw.com\/"},{"@type":"ListItem","position":2,"name":"B\u00dcLTENLER","item":"https:\/\/www.bayraklaw.com\/bultenler\/"},{"@type":"ListItem","position":3,"name":"Sosyal G\u00fcvenlik Kurumu&#8217;nun (SGK) Kar\u015f\u0131lamad\u0131\u011f\u0131 Kanser \u0130la\u00e7lar\u0131 i\u00e7in Hukuki Yollar"}]},{"@type":"WebSite","@id":"https:\/\/www.bayraklaw.com\/#website","url":"https:\/\/www.bayraklaw.com\/","name":"Bayrak Hukuk B\u00fcrosu","description":"","publisher":{"@id":"https:\/\/www.bayraklaw.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.bayraklaw.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/www.bayraklaw.com\/#organization","name":"Bayrak Hukuk B\u00fcrosu","url":"https:\/\/www.bayraklaw.com\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.bayraklaw.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.bayraklaw.com\/wp-content\/uploads\/2025\/03\/Black-and-Yellow-Lines-Attorney-Law-Logo-2-kopyasi.png","contentUrl":"https:\/\/www.bayraklaw.com\/wp-content\/uploads\/2025\/03\/Black-and-Yellow-Lines-Attorney-Law-Logo-2-kopyasi.png","width":1558,"height":860,"caption":"Bayrak Hukuk B\u00fcrosu"},"image":{"@id":"https:\/\/www.bayraklaw.com\/#\/schema\/logo\/image\/"},"sameAs":["http:\/\/linkedin.com\/company\/bayrak-law"]}]}},"_links":{"self":[{"href":"https:\/\/www.bayraklaw.com\/en\/wp-json\/wp\/v2\/portfolio\/924","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bayraklaw.com\/en\/wp-json\/wp\/v2\/portfolio"}],"about":[{"href":"https:\/\/www.bayraklaw.com\/en\/wp-json\/wp\/v2\/types\/portfolio"}],"author":[{"embeddable":true,"href":"https:\/\/www.bayraklaw.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bayraklaw.com\/en\/wp-json\/wp\/v2\/comments?post=924"}],"wp:attachment":[{"href":"https:\/\/www.bayraklaw.com\/en\/wp-json\/wp\/v2\/media?parent=924"}],"wp:term":[{"taxonomy":"portfolio_cat","embeddable":true,"href":"https:\/\/www.bayraklaw.com\/en\/wp-json\/wp\/v2\/portfolio_cat?post=924"},{"taxonomy":"portfolio_tags","embeddable":true,"href":"https:\/\/www.bayraklaw.com\/en\/wp-json\/wp\/v2\/portfolio_tags?post=924"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}